+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies



Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies



Annals of the Rheumatic Diseases 65(8): 983-989



Understanding of the natural history and basic biology of hepatitis B virus (HBV) has increased greatly in recent years. In view of this, the following are reviewed here: (a) recent advances in HBV biology pertinent to the rheumatic disease population; (b) the risks of HBV reactivation in patients with rheumatic disease undergoing immunosuppression; and (c) potential strategies to manage these risks.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012144331

Download citation: RISBibTeXText

PMID: 16627542

DOI: 10.1136/ard.2005.043257


Related references

Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Current Opinion in Rheumatology 20(4): 443-449, 2008

Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice. Acta Reumatologica Portuguesa 36(2): 110-118, 2011

SAT0140Prevalence of Reactivation of Hepatitis B Virus (HBV) in Patients with Resolved Hbv Hepatitis on Immunosuppressive Therapy for Rheumatic Disease: Multicentre Prospective Observational Study in Japan. Annals of the Rheumatic Diseases 75(Suppl 2): 715.1-715, 2016

Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?. Journal of Rheumatology 39(6): 1292-3; Author Reply 1293, 2012

Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy. Hepatology 50(2): 654-655, 2009

Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clinical Rheumatology 33(4): 577-586, 2015

Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. Journal of Rheumatology 38(10): 2209-2214, 2012

Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Annals of the Rheumatic Diseases 76(6): 1051-1056, 2016

Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. Rheumatology International 36(5): 635-641, 2017

Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: IV. Recent topics: 1. Reactivation of hepatitis B virus and hepatitis C virus following immunosuppressive therapy. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 103(7): 1645-1653, 2014

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Research and Therapy 20(1): 246, 2018

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. International Journal of Rheumatic Diseases 16(5): 527-531, 2014

Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. European Journal of Gastroenterology and Hepatology 30(8): 925-929, 2018

Universal hepatitis B virus screening in patients receiving immunosuppressive therapy: a small step for the oncologists, a major advance for prevention of hepatitis B virus reactivation. Clinical Gastroenterology and Hepatology 13(5): 976-978, 2016

Prophylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy. Ugeskrift for Laeger 181(6), 2019